Pacira BioSciences, Inc.
Balance Sheet
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $205.9M | $144.3M | $158.5M | $147.6M | $300.5M | $283.6M | $276.8M | $246.0M |
| Accounts Receivable | $132.4M | $125.6M | $124.1M | $115.3M | $114.4M | $104.7M | $113.3M | $100.7M |
| Inventory | $134.6M | $150.4M | $152.9M | $157.7M | $148.2M | $133.8M | $125.3M | $111.9M |
| Total Current Assets | $615.2M | $515.0M | $548.0M | $562.8M | $745.6M | $760.0M | $745.1M | $690.0M |
| Property, Plant & Equipment | $130.3M | $136.3M | $140.7M | $147.4M | $155.2M | $164.5M | $167.2M | $166.9M |
| Goodwill | $19.6M | $19.8M | $20.2M | $20.3M | $20.3M | $21.5M | $0 | $0 |
| Intangible Assets (Excl. Goodwill) | $285.5M | $353.2M | $368.1M | $382.4M | $422.6M | $435.0M | $426.0M | $440.3M |
| Total Assets | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B |
| Liabilities | ||||||||
| Accounts Payable | $17.5M | $14.0M | $15.2M | $17.7M | $30.1M | $23.2M | $19.1M | $19.4M |
| Total Current Liabilities | $122.0M | $108.8M | $120.6M | $107.1M | $313.2M | $314.7M | $309.9M | $306.4M |
| Long-Term Debt | $363.1M | $367.7M | $372.2M | $376.7M | $580.5M | $583.4M | $383.5M | — |
| Total Liabilities | $572.0M | $554.6M | $571.8M | $570.4M | $779.5M | $788.1M | $775.2M | $772.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-191.8M | $-196.4M | $-199.3M | $-201.0M | $-206.4M | $-201.5M | $-206.4M | $-222.4M |
| Total Stockholders' Equity | $672.0M | $653.9M | $693.1M | $727.2M | $757.8M | $798.5M | $778.3M | $749.6M |